COVID-19 intranasal vaccines: current progress, advantages, prospects, and challenges

Multiple vaccines have recently been developed, and almost all the countries are presently vaccinating their population to tackle the COVID-19 pandemic. Most of the COVID-19 vaccines in use are administered via intramuscular (IM) injection, eliciting protective humor and cellular immunity. COVID-19...

Full description

Saved in:
Bibliographic Details
Published inHuman vaccines & immunotherapeutics Vol. 18; no. 5; p. 2045853
Main Authors Dhama, Kuldeep, Dhawan, Manish, Tiwari, Ruchi, Emran, Talha Bin, Mitra, Saikat, Rabaan, Ali A., Alhumaid, Saad, Alawi, Zainab Al, Al Mutair, Abbas
Format Journal Article
LanguageEnglish
Published United States Taylor & Francis 30.11.2022
Taylor & Francis Group
Subjects
Administration, Intranasal
Antibodies, Viral
Coronavirus – Mini-Review
COVID-19
COVID-19 - prevention & control
COVID-19 Vaccines
Humans
intranasal vaccine
mucosal immunity
Pandemics
Review
SARS-CoV-2
COVID-19
intranasal vaccine
SARS-CoV-2
mucosal immunity
Online AccessGet full text

Cover

Abstract Multiple vaccines have recently been developed, and almost all the countries are presently vaccinating their population to tackle the COVID-19 pandemic. Most of the COVID-19 vaccines in use are administered via intramuscular (IM) injection, eliciting protective humor and cellular immunity. COVID-19 intranasal (IN) vaccines are also being developed that have shown promising ability to induce a significant amount of antibody-mediated immune response and a robust cell-mediated immunity as well as hold the added ability to stimulate protective mucosal immunity along with the additional advantage of the ease of administration as compared to IM injected vaccines. By inducing secretory IgA antibody responses specifically in the nasal compartment, the intranasal SARS-CoV-2 vaccine can prevent virus infection, replication, shedding, and disease development, as well as possibly limits virus transmission. This article highlights the current progress, advantages, prospects, and challenges in developing intranasal COVID-19 vaccines for countering the ongoing pandemic.
AbstractList Multiple vaccines have recently been developed, and almost all the countries are presently vaccinating their population to tackle the COVID-19 pandemic. Most of the COVID-19 vaccines in use are administered via intramuscular (IM) injection, eliciting protective humor and cellular immunity. COVID-19 intranasal (IN) vaccines are also being developed that have shown promising ability to induce a significant amount of antibody-mediated immune response and a robust cell-mediated immunity as well as hold the added ability to stimulate protective mucosal immunity along with the additional advantage of the ease of administration as compared to IM injected vaccines. By inducing secretory IgA antibody responses specifically in the nasal compartment, the intranasal SARS-CoV-2 vaccine can prevent virus infection, replication, shedding, and disease development, as well as possibly limits virus transmission. This article highlights the current progress, advantages, prospects, and challenges in developing intranasal COVID-19 vaccines for countering the ongoing pandemic.Multiple vaccines have recently been developed, and almost all the countries are presently vaccinating their population to tackle the COVID-19 pandemic. Most of the COVID-19 vaccines in use are administered via intramuscular (IM) injection, eliciting protective humor and cellular immunity. COVID-19 intranasal (IN) vaccines are also being developed that have shown promising ability to induce a significant amount of antibody-mediated immune response and a robust cell-mediated immunity as well as hold the added ability to stimulate protective mucosal immunity along with the additional advantage of the ease of administration as compared to IM injected vaccines. By inducing secretory IgA antibody responses specifically in the nasal compartment, the intranasal SARS-CoV-2 vaccine can prevent virus infection, replication, shedding, and disease development, as well as possibly limits virus transmission. This article highlights the current progress, advantages, prospects, and challenges in developing intranasal COVID-19 vaccines for countering the ongoing pandemic.
Multiple vaccines have recently been developed, and almost all the countries are presently vaccinating their population to tackle the COVID-19 pandemic. Most of the COVID-19 vaccines in use are administered via intramuscular (IM) injection, eliciting protective humor and cellular immunity. COVID-19 intranasal (IN) vaccines are also being developed that have shown promising ability to induce a significant amount of antibody-mediated immune response and a robust cell-mediated immunity as well as hold the added ability to stimulate protective mucosal immunity along with the additional advantage of the ease of administration as compared to IM injected vaccines. By inducing secretory IgA antibody responses specifically in the nasal compartment, the intranasal SARS-CoV-2 vaccine can prevent virus infection, replication, shedding, and disease development, as well as possibly limits virus transmission. This article highlights the current progress, advantages, prospects, and challenges in developing intranasal COVID-19 vaccines for countering the ongoing pandemic.
Author Mitra, Saikat
Dhama, Kuldeep
Rabaan, Ali A.
Al Mutair, Abbas
Dhawan, Manish
Alhumaid, Saad
Emran, Talha Bin
Tiwari, Ruchi
Alawi, Zainab Al
Author_xml – sequence: 1
  givenname: Kuldeep
  orcidid: 0000-0001-7469-4752
  surname: Dhama
  fullname: Dhama, Kuldeep
  email: kdhama@rediffmail.com
  organization: ICAR-Indian Veterinary Research Institute
– sequence: 2
  givenname: Manish
  orcidid: 0000-0002-7783-7138
  surname: Dhawan
  fullname: Dhawan, Manish
  organization: The Trafford Group of Colleges
– sequence: 3
  givenname: Ruchi
  orcidid: 0000-0001-7763-5547
  surname: Tiwari
  fullname: Tiwari, Ruchi
  organization: Uttar Pradesh Pandit Deen Dayal Upadhyaya Pashu Chikitsa Vigyan Vishwavidyalaya Evam Go Anusandhan Sansthan (DUVASU)
– sequence: 4
  givenname: Talha Bin
  orcidid: 0000-0003-3188-2272
  surname: Emran
  fullname: Emran, Talha Bin
  organization: BGC Trust University Bangladesh
– sequence: 5
  givenname: Saikat
  surname: Mitra
  fullname: Mitra, Saikat
  organization: University of Dhaka
– sequence: 6
  givenname: Ali A.
  orcidid: 0000-0002-6774-9847
  surname: Rabaan
  fullname: Rabaan, Ali A.
  organization: The University of Haripur
– sequence: 7
  givenname: Saad
  orcidid: 0000-0003-4552-4513
  surname: Alhumaid
  fullname: Alhumaid, Saad
  organization: Ministry of Health
– sequence: 8
  givenname: Zainab Al
  orcidid: 0000-0002-7004-7694
  surname: Alawi
  fullname: Alawi, Zainab Al
  organization: King Faisal University
– sequence: 9
  givenname: Abbas
  orcidid: 0000-0002-9471-2767
  surname: Al Mutair
  fullname: Al Mutair, Abbas
  organization: Wollongong University
BackLink https://www.ncbi.nlm.nih.gov/pubmed/35258416$$D View this record in MEDLINE/PubMed
BookMark eNp9UU1vEzEQXaEiWkp_AmiPHNjir7E3HBAofEWq1EtB3KyJP9KtHDvYm6D-e7wkjegFH8ajN2_ejOY9b05iiq5pXlJySUlP3jIqBQCFS0YYq0FAD_xJczbhHYD4eXLMKZw2F6XckfoUYULKZ80pBwa9oPKs-T6__rH41NFZO8QxY8SCod2hMUN05V1rtjm7OLabnFbZlfKmRbvDOOLK1byiZePMOMHRtuYWQ3Cxll40Tz2G4i4O_3lz8-Xzzfxbd3X9dTH_eNUZ4GLsloIZzpziyjpKFWUMhOWMO-Gh97IHMLJ3TFGivEcEWBJjmHIEhZgR5OfNYi9rE97pTR7WmO91wkH_BVJeaczjYILTEg01lng2Myis9f1M-WXdAg0xSjJbtd7vtTbb5dpZ46ZzhEeijytxuNWrtNP9jIMAWQVeHwRy-rV1ZdTroRgXAkaXtkUzyRXnCqioVNhTTT1gyc4fx1CiJ4P1g8F6MlgfDK59r_7d8dj1YGclfNgThuhTXuPvlIPVI96HlH111wxF8__P-APQkbb4
CitedBy_id crossref_primary_10_1007_s11010_023_04848_3
crossref_primary_10_18006_2023_11_1__150_157
crossref_primary_10_1007_s43440_023_00463_7
crossref_primary_10_3390_vaccines11091502
crossref_primary_10_1016_j_it_2023_01_005
crossref_primary_10_4236_ojbiphy_2023_133004
crossref_primary_10_3390_bioengineering9120816
crossref_primary_10_1016_j_biopha_2023_115597
crossref_primary_10_1016_j_molmed_2022_10_009
crossref_primary_10_1007_s43440_022_00425_5
crossref_primary_10_3389_fimmu_2023_1185278
crossref_primary_10_1016_j_bbr_2023_114662
crossref_primary_10_1007_s11684_023_1034_6
crossref_primary_10_3389_fcimb_2022_979641
crossref_primary_10_1088_1361_6528_ad1644
crossref_primary_10_3390_vaccines11121749
crossref_primary_10_3389_fimmu_2023_1183258
crossref_primary_10_3389_fimmu_2023_1197649
crossref_primary_10_3389_fneur_2024_1396642
crossref_primary_10_1002_mco2_167
crossref_primary_10_1080_22221751_2022_2119169
crossref_primary_10_1021_acschemneuro_3c00488
crossref_primary_10_3389_fimmu_2022_923106
crossref_primary_10_3390_vaccines11061045
crossref_primary_10_1016_j_autrev_2023_103340
crossref_primary_10_1016_j_heliyon_2024_e29939
crossref_primary_10_3390_v15112277
crossref_primary_10_4103_ecdt_ecdt_122_22
crossref_primary_10_1007_s44187_024_00075_x
crossref_primary_10_1016_j_isci_2023_107612
crossref_primary_10_1038_s41598_023_42539_7
crossref_primary_10_1097_JS9_0000000000000046
crossref_primary_10_17816_clinpract111120
crossref_primary_10_1016_j_hsr_2023_100127
crossref_primary_10_1016_S2213_2600_23_00349_1
crossref_primary_10_3390_vaccines11020455
crossref_primary_10_3390_vaccines10122150
crossref_primary_10_1208_s12249_024_02778_x
crossref_primary_10_1080_19932820_2023_2209949
crossref_primary_10_3390_ijms23116083
crossref_primary_10_3390_v16060865
crossref_primary_10_3389_fimmu_2023_1166765
crossref_primary_10_3390_vaccines11030682
crossref_primary_10_3390_vaccines10071072
crossref_primary_10_1016_j_envres_2023_116823
Cites_doi 10.1016/j.chom.2020.12.010
10.1016/j.ijpharm.2019.118731
10.1080/21645515.2020.1805992
10.1016/j.ijbiomac.2021.05.155
10.1002/rmv.2205
10.1038/nri1777
10.1016/S1473-3099(21)00396-0
10.3390/pharmaceutics13020140
10.1016/j.drudis.2021.07.021
10.1056/NEJMoa030595
10.1177/0194599820982633
10.1186/s12951-021-00806-7
10.1080/21645515.2020.1833579
10.1080/21645515.2020.1871295
10.1080/21645515.2020.1826249
10.1007/s13346-021-01001-9
10.3390/pharmaceutics13050644
10.1021/ci400128m
10.1016/j.jsps.2020.12.018
10.1016/j.xcrm.2021.100230
10.1002/jps.20718
10.1016/j.celrep.2021.109452
10.1097/QCO.0000000000000724
10.1080/21645515.2020.1842683
10.3390/vaccines9050433
10.1089/vim.2017.0026
10.1080/14712598.2020.1796963
10.3390/vaccines9010021
10.1016/j.arcmed.2021.04.006
10.3390/vaccines9050524
10.1155/2016/5482087
10.1172/jci.insight.148494
10.1038/d41586-021-00728-2
10.3390/ijms222312638
10.1007/s13238-014-0125-1
10.1007/s40005-021-00520-4
10.1021/acschemneuro.0c00172
10.1016/j.ijsu.2021.106119
10.1177/1753465808093933
10.1056/NEJMoa2035389
10.1002/jmv.26769
10.1080/14760584.2019.1604231
10.3390/vaccines9080881
10.1038/s41541-021-00292-w
10.1080/21645515.2020.1842034
10.4049/jimmunol.165.9.4778
10.1016/j.cell.2020.08.026
10.1080/21645515.2021.1926183
10.1016/j.arcmed.2020.09.010
10.3390/vaccines9020171
10.1016/S0140-6736(20)32623-4
10.26355/eurrev_202101_24613
10.1038/s41385-020-00359-2
10.1016/j.ebiom.2022.103841
10.1101/2021.01.08.425974
10.1056/NEJMc2036242
10.1016/j.vaccine.2021.03.059
10.1016/j.mehy.2020.110084
10.3390/vaccines9080910
10.3389/fimmu.2020.591897
10.1016/j.ijpharm.2021.120686
10.1128/JVI.77.18.10078-10087.2003
10.3390/vaccines8040584
10.3390/vaccines9070768
10.1080/21645515.2021.1920272
10.1101/2021.01.09.426058
10.3390/vaccines9020132
10.1101/2021.01.19.426885
10.1016/j.smim.2018.05.001
10.2174/1871526521666210218201113
10.1038/s41541-021-00290-y
10.1016/j.vaccine.2021.03.006
10.1126/scitranslmed.abh0755
10.1128/CMR.00028-20
10.1016/j.smim.2020.101426
10.1016/j.jinorgbio.2021.111454
10.1080/21645515.2020.1788310
10.1016/j.vaccine.2020.10.056
10.1080/21645515.2021.1923350
10.1016/j.medj.2020.12.004
10.1080/21645515.2020.1830683
10.1016/j.vaccine.2020.11.054
10.2139/ssrn.3751056
10.1038/s41573-021-00163-y
10.1021/acs.molpharmaceut.0c01256
10.1016/j.biopha.2021.111272
10.1093/jtm/taab064
10.1002/eji.202149167
10.1038/srep22404
10.2217/fmb-2020-0293
10.1016/j.ejphar.2020.173751
10.2139/ssrn.3773804
ContentType Journal Article
Copyright 2022 The Author(s). Published with license by Taylor & Francis Group, LLC. 2022
2022 The Author(s). Published with license by Taylor & Francis Group, LLC. 2022 The Author(s)
Copyright_xml – notice: 2022 The Author(s). Published with license by Taylor & Francis Group, LLC. 2022
– notice: 2022 The Author(s). Published with license by Taylor & Francis Group, LLC. 2022 The Author(s)
DBID 0YH
CGR
CUY
CVF
ECM
EIF
NPM
AAYXX
CITATION
7X8
5PM
DOA
DOI 10.1080/21645515.2022.2045853
DatabaseName Taylor & Francis (Open access)
Medline
MEDLINE
MEDLINE (Ovid)
MEDLINE
MEDLINE
PubMed
CrossRef
MEDLINE - Academic
PubMed Central (Full Participant titles)
DOAJ Directory of Open Access Journals
DatabaseTitle MEDLINE
Medline Complete
MEDLINE with Full Text
PubMed
MEDLINE (Ovid)
CrossRef
MEDLINE - Academic
DatabaseTitleList MEDLINE - Academic


MEDLINE
Database_xml – sequence: 1
  dbid: DOA
  name: Directory of Open Access Journals
  url: https://www.doaj.org/
  sourceTypes: Open Website
– sequence: 2
  dbid: NPM
  name: PubMed
  url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
– sequence: 3
  dbid: EIF
  name: MEDLINE
  url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search
  sourceTypes: Index Database
– sequence: 4
  dbid: 0YH
  name: Taylor & Francis (Open access)
  url: https://www.tandfonline.com
  sourceTypes: Publisher
DeliveryMethod fulltext_linktorsrc
Discipline Biology
DocumentTitleAlternate K. DHAMA ET AL
EISSN 2164-554X
ExternalDocumentID oai_doaj_org_article_6ac1cd0f29ca4ddf897fbc53ac0c762d
10_1080_21645515_2022_2045853
35258416
2045853
Genre Coronavirus - Mini-Review
Journal Article
Review
GrantInformation_xml – fundername: no funding
GroupedDBID ---
00X
0R~
0YH
30N
4.4
53G
AAJNR
AALUX
ABEIZ
ABUPF
ACENM
ACGFS
ADBBV
ADCVX
ADFCX
AECIN
AENEX
AEXWM
AIJEM
AIRBT
ALMA_UNASSIGNED_HOLDINGS
ALQZU
AOIJS
ARJSQ
BABNJ
BAWUL
BLEHA
BOHLJ
CCCUG
DGEBU
DIK
EBS
EMOBN
GROUPED_DOAJ
HYE
KYCEM
LJTGL
M4Z
O9-
RIG
RPM
SV3
TFL
TFW
TTHFI
UHWXJ
ZGOLN
AGYJP
CGR
CUY
CVF
ECM
EIF
NPM
AAYXX
CITATION
H13
TDBHL
7X8
5PM
ID FETCH-LOGICAL-c534t-b42c32e737de11712254d323e4f58f6855c68e27107ffaa55b0cc27e0a4490a3
IEDL.DBID RPM
ISSN 2164-5515
2164-554X
IngestDate Thu Jul 04 21:07:17 EDT 2024
Tue Sep 17 21:15:38 EDT 2024
Thu Sep 05 16:31:19 EDT 2024
Fri Aug 23 04:04:16 EDT 2024
Sun Jun 23 00:36:09 EDT 2024
Tue Feb 06 04:20:23 EST 2024
IsDoiOpenAccess true
IsOpenAccess true
IsPeerReviewed true
IsScholarly true
Issue 5
Keywords COVID-19
intranasal vaccine
SARS-CoV-2
mucosal immunity
Language English
License open-access: http://creativecommons.org/licenses/by-nc-nd/4.0/: This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives License (http://creativecommons.org/licenses/by-nc-nd/4.0/), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited, and is not altered, transformed, or built upon in any way.
This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives License (http://creativecommons.org/licenses/by-nc-nd/4.0/), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited, and is not altered, transformed, or built upon in any way.
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-c534t-b42c32e737de11712254d323e4f58f6855c68e27107ffaa55b0cc27e0a4490a3
Notes ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
ObjectType-Review-3
content type line 23
ORCID 0000-0002-7004-7694
0000-0002-6774-9847
0000-0003-4552-4513
0000-0002-9471-2767
0000-0003-3188-2272
0000-0001-7469-4752
0000-0001-7763-5547
0000-0002-7783-7138
OpenAccessLink https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8935456/
PMID 35258416
PQID 2637337514
PQPubID 23479
ParticipantIDs crossref_primary_10_1080_21645515_2022_2045853
proquest_miscellaneous_2637337514
pubmed_primary_35258416
informaworld_taylorfrancis_310_1080_21645515_2022_2045853
doaj_primary_oai_doaj_org_article_6ac1cd0f29ca4ddf897fbc53ac0c762d
pubmedcentral_primary_oai_pubmedcentral_nih_gov_8935456
PublicationCentury 2000
PublicationDate 2022-11-30
PublicationDateYYYYMMDD 2022-11-30
PublicationDate_xml – month: 11
  year: 2022
  text: 2022-11-30
  day: 30
PublicationDecade 2020
PublicationPlace United States
PublicationPlace_xml – name: United States
PublicationTitle Human vaccines & immunotherapeutics
PublicationTitleAlternate Hum Vaccin Immunother
PublicationYear 2022
Publisher Taylor & Francis
Taylor & Francis Group
Publisher_xml – name: Taylor & Francis
– name: Taylor & Francis Group
References e_1_3_4_3_1
e_1_3_4_61_1
e_1_3_4_84_1
e_1_3_4_42_1
e_1_3_4_80_1
e_1_3_4_7_1
e_1_3_4_23_1
e_1_3_4_46_1
e_1_3_4_69_1
e_1_3_4_27_1
e_1_3_4_65_1
e_1_3_4_88_1
Piret J (e_1_3_4_32_1) 2021; 11
e_1_3_4_102_1
e_1_3_4_72_1
e_1_3_4_95_1
e_1_3_4_106_1
e_1_3_4_53_1
e_1_3_4_91_1
e_1_3_4_30_1
e_1_3_4_34_1
e_1_3_4_11_1
e_1_3_4_76_1
e_1_3_4_99_1
e_1_3_4_38_1
WHO (e_1_3_4_13_1) 2020
e_1_3_4_15_1
e_1_3_4_57_1
e_1_3_4_2_1
e_1_3_4_62_1
e_1_3_4_85_1
e_1_3_4_20_1
e_1_3_4_6_1
e_1_3_4_81_1
e_1_3_4_24_1
e_1_3_4_43_1
e_1_3_4_28_1
e_1_3_4_66_1
e_1_3_4_47_1
e_1_3_4_89_1
e_1_3_4_101_1
e_1_3_4_73_1
e_1_3_4_105_1
e_1_3_4_96_1
e_1_3_4_31_1
e_1_3_4_50_1
e_1_3_4_92_1
e_1_3_4_12_1
e_1_3_4_35_1
e_1_3_4_58_1
e_1_3_4_16_1
e_1_3_4_39_1
e_1_3_4_77_1
e_1_3_4_63_1
e_1_3_4_86_1
e_1_3_4_9_1
e_1_3_4_40_1
e_1_3_4_82_1
e_1_3_4_5_1
e_1_3_4_21_1
e_1_3_4_44_1
e_1_3_4_25_1
e_1_3_4_48_1
e_1_3_4_29_1
e_1_3_4_100_1
e_1_3_4_104_1
e_1_3_4_74_1
e_1_3_4_97_1
e_1_3_4_51_1
e_1_3_4_70_1
e_1_3_4_93_1
e_1_3_4_59_1
e_1_3_4_55_1
e_1_3_4_17_1
e_1_3_4_78_1
e_1_3_4_36_1
e_1_3_4_4_1
e_1_3_4_83_1
e_1_3_4_64_1
e_1_3_4_8_1
e_1_3_4_41_1
Rao VB (e_1_3_4_19_1) 2021
e_1_3_4_60_1
e_1_3_4_45_1
e_1_3_4_22_1
e_1_3_4_49_1
e_1_3_4_87_1
e_1_3_4_26_1
e_1_3_4_68_1
e_1_3_4_103_1
e_1_3_4_94_1
e_1_3_4_75_1
e_1_3_4_107_1
e_1_3_4_90_1
e_1_3_4_71_1
e_1_3_4_10_1
e_1_3_4_33_1
e_1_3_4_98_1
e_1_3_4_14_1
e_1_3_4_37_1
e_1_3_4_56_1
e_1_3_4_79_1
e_1_3_4_18_1
References_xml – ident: e_1_3_4_46_1
  doi: 10.1016/j.chom.2020.12.010
– ident: e_1_3_4_93_1
  doi: 10.1016/j.ijpharm.2019.118731
– ident: e_1_3_4_38_1
  doi: 10.1080/21645515.2020.1805992
– ident: e_1_3_4_95_1
  doi: 10.1016/j.ijbiomac.2021.05.155
– ident: e_1_3_4_15_1
  doi: 10.1002/rmv.2205
– ident: e_1_3_4_87_1
  doi: 10.1038/nri1777
– ident: e_1_3_4_51_1
  doi: 10.1016/S1473-3099(21)00396-0
– ident: e_1_3_4_102_1
  doi: 10.3390/pharmaceutics13020140
– ident: e_1_3_4_56_1
  doi: 10.1016/j.drudis.2021.07.021
– ident: e_1_3_4_85_1
  doi: 10.1056/NEJMoa030595
– ident: e_1_3_4_37_1
  doi: 10.1177/0194599820982633
– ident: e_1_3_4_17_1
  doi: 10.1186/s12951-021-00806-7
– ident: e_1_3_4_100_1
  doi: 10.1080/21645515.2020.1833579
– ident: e_1_3_4_8_1
  doi: 10.1080/21645515.2020.1871295
– ident: e_1_3_4_24_1
  doi: 10.1080/21645515.2020.1826249
– ident: e_1_3_4_42_1
  doi: 10.1007/s13346-021-01001-9
– ident: e_1_3_4_101_1
  doi: 10.3390/pharmaceutics13050644
– ident: e_1_3_4_107_1
  doi: 10.1021/ci400128m
– ident: e_1_3_4_6_1
  doi: 10.1016/j.jsps.2020.12.018
– ident: e_1_3_4_53_1
– ident: e_1_3_4_70_1
  doi: 10.1016/j.xcrm.2021.100230
– ident: e_1_3_4_106_1
  doi: 10.1002/jps.20718
– ident: e_1_3_4_49_1
  doi: 10.1016/j.celrep.2021.109452
– ident: e_1_3_4_78_1
  doi: 10.1097/QCO.0000000000000724
– ident: e_1_3_4_29_1
  doi: 10.1080/21645515.2020.1842683
– ident: e_1_3_4_11_1
  doi: 10.3390/vaccines9050433
– ident: e_1_3_4_92_1
  doi: 10.1089/vim.2017.0026
– ident: e_1_3_4_55_1
– ident: e_1_3_4_4_1
  doi: 10.1080/14712598.2020.1796963
– ident: e_1_3_4_28_1
  doi: 10.3390/vaccines9010021
– ident: e_1_3_4_75_1
  doi: 10.1016/j.drudis.2021.07.021
– ident: e_1_3_4_25_1
  doi: 10.1016/j.arcmed.2021.04.006
– ident: e_1_3_4_82_1
  doi: 10.3390/vaccines9050524
– ident: e_1_3_4_88_1
  doi: 10.1155/2016/5482087
– ident: e_1_3_4_47_1
  doi: 10.1172/jci.insight.148494
– ident: e_1_3_4_27_1
  doi: 10.1038/d41586-021-00728-2
– ident: e_1_3_4_99_1
  doi: 10.3390/ijms222312638
– ident: e_1_3_4_65_1
– ident: e_1_3_4_91_1
  doi: 10.1007/s13238-014-0125-1
– ident: e_1_3_4_5_1
  doi: 10.1007/s40005-021-00520-4
– ident: e_1_3_4_104_1
  doi: 10.1021/acschemneuro.0c00172
– ident: e_1_3_4_83_1
  doi: 10.1016/j.ijsu.2021.106119
– volume: 11
  start-page: 8
  year: 2021
  ident: e_1_3_4_32_1
  article-title: COVID-19 vaccines: where we stand and challenges ahead
  publication-title: Cell Death Differ
  contributor:
    fullname: Piret J
– ident: e_1_3_4_97_1
  doi: 10.1177/1753465808093933
– ident: e_1_3_4_21_1
  doi: 10.1056/NEJMoa2035389
– ident: e_1_3_4_40_1
  doi: 10.1002/jmv.26769
– ident: e_1_3_4_98_1
  doi: 10.1080/14760584.2019.1604231
– ident: e_1_3_4_44_1
  doi: 10.3390/vaccines9080881
– ident: e_1_3_4_81_1
  doi: 10.1038/s41541-021-00292-w
– ident: e_1_3_4_14_1
  doi: 10.1080/21645515.2020.1842034
– year: 2021
  ident: e_1_3_4_19_1
  article-title: A universal Bacteriophage T4 nanoparticle platform to design Multiplex SARS-CoV-2 vaccine candidates by CRISPR Engineering
  publication-title: bioRxiv
  contributor:
    fullname: Rao VB
– ident: e_1_3_4_96_1
  doi: 10.4049/jimmunol.165.9.4778
– ident: e_1_3_4_69_1
  doi: 10.1016/j.cell.2020.08.026
– ident: e_1_3_4_2_1
– ident: e_1_3_4_30_1
  doi: 10.1080/21645515.2021.1926183
– ident: e_1_3_4_7_1
  doi: 10.1016/j.arcmed.2020.09.010
– ident: e_1_3_4_10_1
  doi: 10.3390/vaccines9020171
– ident: e_1_3_4_22_1
  doi: 10.1016/S0140-6736(20)32623-4
– ident: e_1_3_4_34_1
  doi: 10.26355/eurrev_202101_24613
– ident: e_1_3_4_80_1
  doi: 10.1038/s41385-020-00359-2
– ident: e_1_3_4_84_1
  doi: 10.1016/j.ebiom.2022.103841
– ident: e_1_3_4_36_1
  doi: 10.1101/2021.01.08.425974
– ident: e_1_3_4_20_1
  doi: 10.1056/NEJMc2036242
– ident: e_1_3_4_57_1
  doi: 10.1016/j.vaccine.2021.03.059
– ident: e_1_3_4_63_1
  doi: 10.1016/j.mehy.2020.110084
– ident: e_1_3_4_77_1
  doi: 10.3390/vaccines9080910
– ident: e_1_3_4_39_1
  doi: 10.3389/fimmu.2020.591897
– ident: e_1_3_4_35_1
  doi: 10.1016/j.ijpharm.2021.120686
– ident: e_1_3_4_59_1
– ident: e_1_3_4_86_1
  doi: 10.1128/JVI.77.18.10078-10087.2003
– ident: e_1_3_4_62_1
  doi: 10.3390/vaccines8040584
– ident: e_1_3_4_73_1
  doi: 10.3390/vaccines9070768
– ident: e_1_3_4_58_1
  doi: 10.1080/21645515.2021.1920272
– ident: e_1_3_4_68_1
  doi: 10.1101/2021.01.09.426058
– ident: e_1_3_4_74_1
  doi: 10.3390/vaccines9020132
– ident: e_1_3_4_79_1
  doi: 10.1101/2021.01.19.426885
– ident: e_1_3_4_89_1
  doi: 10.1016/j.smim.2018.05.001
– ident: e_1_3_4_41_1
  doi: 10.2174/1871526521666210218201113
– ident: e_1_3_4_16_1
  doi: 10.1038/s41541-021-00290-y
– ident: e_1_3_4_50_1
– ident: e_1_3_4_45_1
  doi: 10.1016/j.vaccine.2021.03.006
– ident: e_1_3_4_48_1
  doi: 10.1126/scitranslmed.abh0755
– ident: e_1_3_4_3_1
  doi: 10.1128/CMR.00028-20
– ident: e_1_3_4_94_1
  doi: 10.1016/j.smim.2020.101426
– ident: e_1_3_4_103_1
  doi: 10.1016/j.jinorgbio.2021.111454
– ident: e_1_3_4_9_1
  doi: 10.1080/21645515.2020.1788310
– ident: e_1_3_4_64_1
  doi: 10.1016/j.vaccine.2020.10.056
– ident: e_1_3_4_26_1
  doi: 10.1080/21645515.2021.1923350
– ident: e_1_3_4_23_1
  doi: 10.1016/j.medj.2020.12.004
– ident: e_1_3_4_76_1
  doi: 10.1080/21645515.2020.1830683
– ident: e_1_3_4_18_1
  doi: 10.1016/j.vaccine.2020.11.054
– start-page: 3
  year: 2020
  ident: e_1_3_4_13_1
  article-title: WHO Covid-19. Draft landscape of COVID-19 candidate vaccines
  publication-title: Who
  contributor:
    fullname: WHO
– ident: e_1_3_4_61_1
  doi: 10.2139/ssrn.3751056
– ident: e_1_3_4_90_1
  doi: 10.1038/s41573-021-00163-y
– ident: e_1_3_4_72_1
  doi: 10.1021/acs.molpharmaceut.0c01256
– ident: e_1_3_4_31_1
  doi: 10.1016/j.biopha.2021.111272
– ident: e_1_3_4_66_1
  doi: 10.1093/jtm/taab064
– ident: e_1_3_4_60_1
– ident: e_1_3_4_71_1
  doi: 10.1002/eji.202149167
– ident: e_1_3_4_105_1
  doi: 10.1038/srep22404
– ident: e_1_3_4_33_1
  doi: 10.2217/fmb-2020-0293
– ident: e_1_3_4_12_1
  doi: 10.1016/j.ejphar.2020.173751
– ident: e_1_3_4_43_1
  doi: 10.2139/ssrn.3773804
SSID ssj0000702466
Score 2.5297344
SecondaryResourceType review_article
Snippet Multiple vaccines have recently been developed, and almost all the countries are presently vaccinating their population to tackle the COVID-19 pandemic. Most...
SourceID doaj
pubmedcentral
proquest
crossref
pubmed
informaworld
SourceType Open Website
Open Access Repository
Aggregation Database
Index Database
Publisher
StartPage 2045853
SubjectTerms Administration, Intranasal
Antibodies, Viral
Coronavirus – Mini-Review
COVID-19
COVID-19 - prevention & control
COVID-19 Vaccines
Humans
intranasal vaccine
mucosal immunity
Pandemics
Review
SARS-CoV-2
SummonAdditionalLinks – databaseName: DOAJ Directory of Open Access Journals
  dbid: DOA
  link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV3NSx0xEA9FKPQi2lbd2pYt9Gjq5nvTW2srtlC9aPEW8oleVvGtBf97J8muvCeCl96W2Swkk5nJZGfmNwh9DsQ5KmOPJU8ccxY0dpRH3AnnO-ssUTEXCv85lkdn_Pe5OF9q9ZVzwio8cGXcvrSe-NAlqr3lIaReq-S8YNZ3HhQ5FOtLxNJlqthgBWdPCVRSuA9gcAvEXL7Td_uZlklwPaS5GIuDz8xWDqaC3_8IvfQpH_RxKuXS2XS4gdYnp7L9VheziV7E4TV6WdtM3r1BZwcnf3_9wES3l_nzwS5g8D_rc0x98bX1FaKpLalaYPj22pIYMIKlgWeglmrMTB5C6-fmK4u36PTw5-nBEZ7aKWBgFx-x49QzGhVTIRKiCGgyD4yyyJPok-yF8LKPFFwOlZK1QrjOe6piZznXnWVbaG24GuIOajUoteBOB6sSF045qbjsLfEpKqJFaNCXmZXmuoJmGDJhkc68N5n3ZuJ9g75nhj8MzpjXhQCSYCZJMM9JQoP08naZsfzySLU_iWHPTODTvLcG9CsHTewQr24XhkqmGFPgVzZou-71wzQzlGwO2zZIrUjByjpW3wyXFwXDu88cFPLd_1j4LnqV11IBKd-jtfHmNn4AV2l0H4tW3ANQlg36
  priority: 102
  providerName: Directory of Open Access Journals
– databaseName: Taylor & Francis (Open access)
  dbid: 0YH
  link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV1Lb9QwELagCIkL4s3yUpA4YojfMTcoVAsScGkRnCw_Sy9Z1KRI_Htm4mTVrUAcuCVOnNhjz3jsmfmGkGeJhcB17qiWRVIpkqWBy0xbFWLrg2cmY6Dwx096fSQ_fFWLN-Ewu1XiHrpUoIhJViNz-zAsHnEvOaj4sNAr2N1xjKWSoPKKy-QKB9Ubvfrab-vtMQvMaF4tlliLYrUljudvX9pZoSYg_wswpn9SRi_6VJ5bpA5ukOuzdtm8rtPhJrmU-1vkas03-es2Odr__OX9W8psc4LVez_Ayz99ROP68KqJFaupmXy2QAI-byYPgRFEDlxD6RSWicV9auKShWW4Qw4P3h3ur-mcV4FGJeRIg-RR8GyESZkxw4ClZRJcZFlUV3SnVNRd5qB7mFK8Vyq0MXKTWy-lbb24S_b6TZ_vk8YCdysZbPKmSBVM0EbqzrNYsmFWpRV5sZDS_ajoGY7NoKQL7R3S3s20X5E3SPDtywh-PRVsTo_dzEtO-8hiagu30cuUSmdNCdA1H9sIsh3-as8Plxuns49SE5U48Y8GPF3G1gGjofXE93lzNjiuhRHCgIK5IvfqWG-biZiyaL9dEbMzC3b6sfukP_k-gXl3SEGlH_xHmx-Sa3hbASkfkb3x9Cw_BlVpDE8mZvgN5SUI3A
  priority: 102
  providerName: Taylor & Francis
Title COVID-19 intranasal vaccines: current progress, advantages, prospects, and challenges
URI https://www.tandfonline.com/doi/abs/10.1080/21645515.2022.2045853
https://www.ncbi.nlm.nih.gov/pubmed/35258416
https://www.proquest.com/docview/2637337514/abstract/
https://pubmed.ncbi.nlm.nih.gov/PMC8935456
https://doaj.org/article/6ac1cd0f29ca4ddf897fbc53ac0c762d
Volume 18
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV3daxQxEA-9guCL-O1VPVbw0b3L52bjW3taTqHVh1bqU8inHrR7pbcV_O-dZHfLXSkUfFmW2YRNMpPMJJn5DULvPbGWVqEuKx55yZlXpaU8lFhYh401RIYUKHx0XC1O-dczcbaDxBALk532nV1Om_OLabP8nX0rLy_cbPATm30_moOOTYp_NkIjydjGFj0vvxLUTr6jpLAVKMEiEEPkTo1niZZIsDOkKQ6Lg7mccukkVNB0A7elnjKK_y0M07ss0dsOlRsa6vAxetSblsV-14UnaCc0T9GDLtnk32fodP7tx5dPJVHFMlVvzBoK_zEu3ayvPxauA2oqssMWLH8fiuwe0MJ6A-9AzTGZidz4wg0pWNbP0cnh55P5ouyTKpROMN6WllPHaJBM-kCIJDCfuWeUBR5FHataCFfVgYLhIWM0RgiLnaMyYMO5woa9QLvNqgmvUKFkYoNV3sjIhZW2kryqDXExSKKEH6PpMJT6soPO0KRHJB3YoBMbdM-GMTpIA35TOCFfZ8Lq6pfu-a8r44jzOFLlDPc-1kpGC10zDjtY2OGvapNdus0HH7HLUqLZPQ14N_BWwyxLVyemCavrtaYVA0mTYF2O0cuO1zfNHERnjOSWFGz1Y_sLCHZG8u4Fee-_a75GD1MHOizKN2i3vboOb8FKau0EjfDPBTwZPp7kk4ZJnif_ADSBD0w
link.rule.ids 230,315,733,786,790,870,891,2115,27535,27957,27958,53827,53829,59498,59499,60241,61030
linkProvider National Library of Medicine
linkToHtml http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV3db9MwELfGEIIXvgeFAUHikaTxV5zwtnVMHayDh27am-VPqGDptKZI8NdzdpKprZAQvEUXR_Hlzr5z7u53CL2xWGtSuDItmGcpo7ZKNWEuzbk2udIKCxcKhScnxfiUfTjn51uI97UwMWnf6FlWf7_I6tnXmFt5eWGGfZ7Y8PNkBDY2GP7hDXQT1isRK4f0uAELMDwxSkngMJCCT8D72p0yHwZaIMHZkIRKLAYOc-imE3BBQwxuzUBFHP8NFNM_-aKbKZUrNurwHjrruWtTU75ly0Zn5tcG8OM_s38f3e281mSvvf0Abbn6IbrV9rH8-Qidjj6dHR2kuEpmYV61WsDgH8qEoP3iXWJaDKgk5oLBzvo2iZkHDWxlcA3UWO4ZyLVNTN_dZfEYTQ_fT0fjtOvXkBpOWZNqRgwlTlBhHcYCw1bBLCXUMc9LX5Scm6J0BHwa4b1SnOvcGCJcrhirckV30HY9r91TlFQisKgrq4RnXAtdCFaUChvvBK64HaCsl5G8bFE5JO7ATnv5yiBf2cl3gPaDJK8HB1DtSJhffZHdt5WFMtjY3JPKKGatLyvhNbCmTG7AZsBbq1U9kE38p-LbBiiS_mUCr3ulkbCAQ1RG1W6-XEhSUEGpAMd1gJ60SnQ9zV4nB0isqdcaH-t3QGkiSHinJM_--8lX6PZ4OjmWx0cnH5-jO4GZFvJyF203V0v3ApyxRr-MS-8316Qukw
linkToPdf http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1Lb9QwELagCMSFd2F5BokjefgVJ9xgy6oFWnpoUcXF8hNWbbOrbhYJfj1jJ6l2V0hIvUUTR_Fkxp5xZuYbhN5YrDUpXZWWzLOUUVunmjCXFlybQmmFhQuFwvsH5e4x-3TCT1ZafcWkfaOnWXN2njXTnzG3cn5u8iFPLD_cH4ONDYY_n1ufX0c3YM2SeuWgHjdhAcYnRioJHAhS8Av4UL9TFXmgBRKcD0moxmLgNIeOOgEbNMTh1oxUxPLfQDL9lz-6mVa5Yqcmd9H3gcMuPeU0W7Y6M382wB-v9AnuoTu995q874bcR9dc8wDd7PpZ_n6Ijsdfv-3tpLhOpmFujVrA4F_KhOD94l1iOiyoJOaEwQ77NokZCC1saXAN1Fj2GciNTczQ5WXxCB1NPh6Nd9O-b0NqOGVtqhkxlDhBhXUYCwxbBrOUUMc8r3xZcW7KyhHwbYT3SnGuC2OIcIVirC4U3UZbzaxxT1BSi8Cmrq0SnnEtdClYWSlsvBO45naEskFOct6hc0jcg54OMpZBxrKX8Qh9CNK8HBzAtSNhdvFD9t9XlspgYwtPaqOYtb6qhdfAmjKFAdsBb61XdUG28d-K7xqhSPqfCbweFEfCQg7RGdW42XIhSUkFpQIc2BF63CnS5TQHvRwhsaZia3ys3wHFiWDhvaI8vfKTr9Ctw52J_LJ38PkZuh146ZAvn6Ot9mLpXoBP1uqXcfX9BWu2MRM
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=COVID-19+intranasal+vaccines%3A+current+progress%2C+advantages%2C+prospects%2C+and+challenges&rft.jtitle=Human+vaccines+%26+immunotherapeutics&rft.au=Kuldeep+Dhama&rft.au=Manish+Dhawan&rft.au=Ruchi+Tiwari&rft.au=Talha+Bin+Emran&rft.date=2022-11-30&rft.pub=Taylor+%26+Francis+Group&rft.issn=2164-5515&rft.eissn=2164-554X&rft.volume=18&rft.issue=5&rft_id=info:doi/10.1080%2F21645515.2022.2045853&rft.externalDBID=DOA&rft.externalDocID=oai_doaj_org_article_6ac1cd0f29ca4ddf897fbc53ac0c762d
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=2164-5515&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=2164-5515&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=2164-5515&client=summon